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Background: To determine the serotypes of Streptococcus pneumoniae responsible for pneumonia complicated by
parapneumonic effusion in children, we performed real-time PCR based pneumococcal “serotyping” directly on
parapneumonic fluid samples.
Methods: Specimens were collected at two children’s hospitals in Ontario, Canada from 2009 to 2011. Samples in
which S. pneumoniae was detected by PCR were tested with serotype-specific 5′exonuclease PCR assays for the 13
serotypes contained in the 13-serotype pneumococcal vaccine.
Results: Thirty-five S. pneumoniae PCR-positive pleural samples were studied. Pneumococcal serotyping PCR assays
were positive for 34 of 35 (97%). Serotype 3 was detected most frequently, in 19/35 (54%), followed by serotype
19A in 9/35 (26%), serotype 7 F/A in 4/35 (11%), serotype 1 in 1/35 (3%), and serotype 6A also in 1/35 (3%).
Conclusions: PCR testing demonstrated that the vast majority (97%) of S. pneumoniae parapneumonic effusions were
caused by serotypes present in the 13-serotype vaccine that were not present in the original 7 serotype vaccine. This
suggests that use of the 13-serotype vaccine could potentially prevent many S. pneumoniae pneumonias complicated
by parapneumonic effusion in our region, provided serotype replacement does not occur.
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Pneumonia complicated by parapneumonic effusion is
a severe infection in children that leads to prolonged
hospital stay and risk of intensive care unit admission, as
well as other morbidities [1]. The incidence of pneumonia
complicated by parapneumonic effusion or empyema in
children has increased over the past 10-15 years in many
areas of the world, including the US, Canada, Europe,
Asia, and Australia [2-7]. This increase occurred despite
the introduction of a 7-serotype conjugated Streptococcus
pneumoniae vaccine (pneumococcal conjugated vaccine,
7-serotype, PCV7) for routine childhood immunization
in many of these regions; in some studies, the spike in
parapneumonic effusion incidence appeared to occur
subsequent to the widespread use of PCV7 [3,5], whereas* Correspondence: slinger@cheo.on.ca
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to universal pneumococcal vaccination [2,6-8]. As S.
pneumoniae is the major cause of community-acquired
pneumonia in adults and children, PCV7 vaccination
programs led to dramatic decreases in the number of
children presenting with and admitted for pneumonia;
however, the increase in parapneumonic effusion rates
was unexpected.
Two main hypotheses were generated to explain this
phenomenon. Some investigators believed that the
empyema increase was observed due to a proportional
rise in bacterial pneumonia due to bacteria other than
S. pneumoniae. Grijalva et al., for example, documented a
four-fold rise in staphylococcal empyema in American
infants between 1996-98 and 2005-07 [2]; however, it
should be noted that they did not find corresponding
increases in empyema caused by S. aureus in children aged
2-4 years or in all pediatric patients aged < 18 years [9].Ltd. This is an Open Access article distributed under the terms of the Creative
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parapneumonic effusions resulted from a rise in S. pneu-
moniae infections due to serotypes not present in the
PCV7, referred to as ‘serotype replacement’. Many investi-
gators have shown an association between parapneumonic
effusion/empyema and certain pneumococcal serotypes
both after the introduction of PCV7, including 1, 3, 19A,
and others [7,10-13].
In an earlier study of molecular diagnosis of pneumo-
nia complicated by parapneumonic effusion in children
and youth from two tertiary care pediatric hospital sites in
Ontario, Canada, we performed real-time multiple uniplex
PCR for numerous bacterial pathogens on pleural fluid
samples from 56 different children [14]. A bacterial patho-
gen was detected by PCR in 46/56 (82%) of the pleural
fluids. S. pneumoniae was the most commonly detected
bacterium by PCR, found in 35/56 (63%) of the pleural
samples; in contrast, only 8/56 (14%) children had S.
pneumoniae detected by culture of blood or pleural fluid.
No samples were positive for S. aureus by culture or
PCR. These results suggested that S. pneumoniae was
responsible for most of the pneumonias complicated by
parapneumonic effusion at our hospitals.
The objective of this current study was to determine
which serotypes of S. pneumoniae were responsible for
these infections, and whether the responsible serotypes
were included in the newer 13-serotype pneumococcal
conjugated vaccine (PCV13) vaccine and thus might be
preventable. Of note, in Ontario, Canada, where we per-
formed this study, the 7-serotype pneumococcal vaccine
was introduced in 2005. A 10-serotype pneumococcal
vaccine (Synflorix®) replaced PCV7 in October 2009, and
was itself replaced by PCV13 (Prevnar13®) in November
2010.
As described below, we performed direct molecular
“serotyping” on S. pneumoniae PCR-positive pleural fluid
samples. We used real-time PCR assays for the 7 serotypes
included in PCV7 as well as assays for the 6 additional
serotypes present in PCV13.
Methods
Ethics approval was obtained from the Children’s Hospital
of Eastern Ontario and the McMaster Research Ethics
Review Boards for study of anonymized residual pleural
fluid samples that would otherwise have been discarded.
Pleural and blood culture results were recorded for
comparisons to PCR results, but clinical patient informa-
tion such as age and immunization status was not recorded.
Pleural fluid samples were collected at two children’s hospi-
tals in Ontario, Canada, the Children’s Hospital of Eastern
Ontario and the McMaster Children's Hospital, from 2009
to 2011. Two of the investigators (RS and JP) reviewed
microbiology laboratory specimen records for samples
submitted for pleural fluid culture and admission recordsfor children hospitalized with a diagnosis of pneumonia
and/or parapneumonic effusion. Pleural fluids from
patients without a diagnosis of pneumonia were not
eligible for inclusion.
Thirty-five S. pneumoniae PCR- positive samples col-
lected as part of the earlier study [14] were available for
PCR serotyping. S. pneumoniae was grown in culture
from only 3 of these 35 pleural fluids, likely because
most patients had received antibiotic therapy prior to
pleural fluid specimen collection. Blood cultures were
positive for S. pneumoniae in five additional patients.
Pleural samples had been stored initially in sterile
containers at -80°C; DNA was later extracted with an
automated device (iPrep, Life Technologies, Carlsbad,
CA), and nucleic acid extracts were also stored at -80°C.
Pneumococcal PCR serotyping assays for the 13 sero-
types contained within PCV13 (1, 3, 4, 5, 6A, 6B, 7 F, 9 V,
14, 18C, 19A, 19 F, and 23 F) were performed on these 35
specimens. The sequences of the primers and probes used
for detection of each serotype are shown in an additional
file [see “Streptococcus pneumoniae real-time PCR molecu-
lar serotyping assays used with pleural fluid specimens”,
Additional file 1: Table S1] [15,16]. Serotype-specific assays
were selected for use whenever possible but PCR assays
capable of detecting only the vaccine serotype were not
available for some serotypes. For example, the assay used to
detect the 7 F vaccine serotype also detects the related 7 F
non-vaccine serotype.
Real-time singleplex PCR was performed for each
serotype assay. PCR assays (5′ exonuclease probe type)
were obtained from Life Technologies Inc. PCR reaction
assays were prepared in 10 μL volumes in 96-well PCR
plate. TaqMan Fast Advanced Master Mix (Life Technolo-
gies) was used for amplification. A negative control (no
template) was performed with each sample. PCR plates
were covered with MicroAmp® Optical Adhesive Film
(Life Technologies) to prevent cross-contamination.
PCR was performed with a 96 well fast cycling block on
a ViiA7 thermocyler (Life Technologies) using 40 cycles
of 2-temperature thermocyling (95°C x 15 seconds and
60°C × 30 seconds).
Positive controls were performed for all assays using
DNA extracted from cultures of S. pneumoniae of known
serotypes typed at a national reference laboratory, or, if
cultured isolates for a certain serotype were not available,
DNA oligonucleotides that were identical to the target se-
quences were purchased (Integrated DNA Technologies,
Inc., Coralville, Iowa) and used as positive controls.
Negative (no template) controls were run with each
PCR to ensure cross-contamination had not occurred.
Threshold cycle (Ct) values were obtained, with Ct
values <35 considered to be positive.
For analysis, positive serotype results by PCR were
considered to be PCV13-preventable if they were positive
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possibly vaccine preventable if they were positive with
one of the 4 assays that detected more than one serotype,
and as non-vaccine preventable if they were negative with
all 13 PCR assays.
Results
Thirty-five S. pneumoniae PCR- positive samples were
studied: 13 specimens from 2009, 9 specimens from
2010, and 13 specimens from 2011. Molecular serotyp-
ing detected one of the PCV13 serotypes in 34 of the 35
(97%) S. pneumoniae PCR- positive samples. As shown
in Figure 1, serotype 3 was most frequently detected,
present in nineteen specimens (54%), followed by sero-
types 19A in nine specimens (26%), serotype 7 F/7A in
four specimens (11%), serotype 1 in one specimen (3%),
and serotype 6A also in one specimen (3%).
Of note, traditional serotyping results were available
for four of the eight cases in which S. pneumoniae had
been grown from either pleural fluid or blood culture,
and in all four culture-positive samples results were
concordant with the PCR serotyping results (these were
two positive for serotype 19A, one for serotype 3, and
one for serotype 7 F).
Discussion
Thirty-four of the 35 S. pneumoniae PCR-positive para-
pneumonic fluid samples could be serotyped using PCR
assays for serotypes (3, 19A, 1, 6A, 7 F/A) included in
PCV13. Thirty of these thirty-four were considered defin-
itely PCV13-preventable infections, since the PCR assays
used were specific for one serotype. Four samples were
positive with a PCR assay that detects both serotypes
7 F and 7A, so were classified as having been possibly
PCV13-preventable infections (since serotype 7 F butFigure 1 S. pneumoniae serotypes by direct real-time PCR typing
of pediatric pleural fluid specimens. The five serotypes detected are
included in the newer 13-serotype conjugated S. pneumoniae vaccine
but were not present in original 7-serotype vaccine.not 7A is included in PCV13). One PCR-positive pleural
fluid was negative with all 13 PCR assays and was classi-
fied as not PCV13-preventable.
In contrast to some other studies in which serotype 1
infections have been most common [2,12,13,17], we found
only one case of empyema caused by S. pneumoniae sero-
type 1. The majority of parapneumonic effusions in our
study were found to be caused by serotype 3, which has
recently been reported to be associated with empyema
even in children immunized with PCV13 in Greece [10].
Serotype 19A was the second most frequently detected
serotype by PCR in this study. This serotype was reported
as the most common cause of culture-positive invasive S.
pneumoniae infections in all age groups in Province of
Ontario in 2009 [18].
Notably, the five serotypes detected by PCR (assuming
the serotype 7 detected was indeed 7 F and not 7A) were
all among the six serotypes added to PCV13 that were
not present in the original PCV7. This is similar to stud-
ies in other countries in the post-PCV7 era. For ex-
ample, in an Australian study conducted in 2008-9, 90%
of the pneumococcal serotypes detected in pleural fluid
samples were among the 6 new serotypes in PCV13,
with serotype 19A (41%) and 3 (31%) found most com-
monly [19]. Routine PCV7 use began in Australia in
2005, but PCV10 or PCV13 had not been introduced at
the time of this study. In an American study performed
in 2009, 77% of S. pneumoniae PCR-positive pleural fluid
samples were due to the 6 new serotypes; serotype 7 F/A
was most frequently detected (47%), while serotypes 19A
and 3 were both detected in 13% of samples [20]. This
study was also conducted after the introduction of PCV7
but prior to use of PCV13.
This study also demonstrated the usefulness of PCR
methods for identification of S. pneumoniae serotypes in
children with parapneumonic effusions, since cultures
are positive for S. pneumoniae in only a minority of pa-
tients of these patients. Our finding that S. pneumoniae
was detected by culture (of blood or pleural fluid) in
only 23% (8/35) of children with PCR-positive pleural
fluid samples is consistent with other reports [17,18].
This suggests that molecular methods such as PCR
are needed to help guide surveillance and vaccination
programs.
A retrospective review of children admitted to one of
the study site hospitals (the Children’s Hospital of Eastern
Ontario) in 2007- 2008, provides some relevant informa-
tion about the epidemiology of pneumonia and effusion in
our region just prior to the start of the S. pneumoniae
serotyping PCR study [1]. In the review, 135 children were
found to have been hospitalized with pneumonia over the
two year period. The mean age at admission was 4.8 years
(range 0-17 years), and 41% had received antibiotics prior
to admission. With regard to parapneumonic effusions in
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cultures, or on average 11/year, and two of 22 (9.1%) sam-
ples were culture- positive. The median length of stay was
longer for those with pleural effusions (9 days) than for
those without effusions (3 days), and presence of pleural
effusion was associated with admission to the intensive
care unit.
During the PCR serotyping study years, the number of
parapneumonic specimens obtained at this site was 22
in 2009, 13 in 2010, and 12 in 2011. Thus, for unknown
reasons, an increase in pleural specimens cultured was
seen in 2009, which then appears to have decreased to
numbers similar to the 2007 and 2008 years.
Our PCR serotyping study has several limitations that
should be noted. From a technical viewpoint, the PCR
assay used for serotype 7 detected both the 7 F vaccine
serotype and the 7A non-vaccine serotype, making it un-
certain as to whether infections that were PCR-positive
with the assay could be prevented with the PCV13 vac-
cine. Unfortunately, no other PCR assay specific for only
7 F could be found in the medical literature.
Another limitation is that since the pleural fluids
assayed were obtained from children with parapneumo-
nic effusions at two children’s hospitals in the Province
of Ontario, Canada, we cannot necessarily generalize our
findings to the entire Provincial population. However, it is
reasonable to hypothesize that our findings may reflect
overall trends in our Province.
An additional limitation is that we are due to the
anonymous nature of the specimens tested we are not
aware of the age or S. pneumoniae vaccine status of the
children whose samples were studied. Since the PCV7
was introduced in 2005 in our Province, it is likely that
some of the children in this study had received the
PCV7 vaccine.
Finally, the number of S. pneumoniae-PCR positive
samples that were available for PCR serotyping (35) was
relatively small. However, this number of samples is
comparable to those obtained in similar studies from the
USA (45 samples) and Australia (43 samples), and reflects
the fact that pneumonia complicated by parapneumonic
effusion is a relatively infrequent infection. As well, despite
the relatively small numbers, we observed a dramatic
difference in the number of cases for which serotyping
could be performed using PCR as compared to culture.
PCR enabled S. pneumoniae serotyping to be performed
for approximately four times more infections (35 patients
vs. 8 patients) than was possible with culture.
Conclusions
In summary, our study suggests that many cases of
pneumococcal pneumonia with empyema that occurred
between 2009 and 2011 in our region might have been
prevented by PCV13 vaccination. We may thereforeobserve a decrease in the incidence of pneumonia com-
plicated by parapneumonic effusion in future now that
PCV13 has been integrated into the Provincial universal
immunization program. However, serotype replacement
with new serotypes not in PCV13 is also a real possibility.
Continued surveillance using molecular serotyping
methods such as real-time PCR is probably the most
effective tool to monitor which S. pneumoniae serotypes
are responsible for pneumonias complicated by parapneu-
monic effusion. This will allow the effectiveness of PCV13
and the need for future development of new pneumococcal
vaccines to be assessed using much more comprehensive
information than is currently available using culture-based
surveillance. Molecular surveillance will also be important
to determine whether or not S. pneumoniae serotype 3
pneumonias with parapneumonic effusion are effectively
prevented by the use of PCV13, as this serotype has caused
infection in some patients immunized with PCV13 [10].
Additional file
Additional file 1: Table S1. Streptococcus pneumoniae real-time PCR
molecular serotyping assays used with pleural fluid specimens.
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